European Pharmaceutical Review

AUGUST 21, 2023

Q2 2023 biopharma market capitalisation results Eli Lilly “Eli Lilly witnessed the largest market capitalisation growth of 36.1 Lilly completes biopharma acquisitions GlobalData highlighted that Eli Lilly reported its synthetic peptide Mounjaro had $980 million in global sales in Q2. trillion in the Q1 of 2023 to $3.56

Biopharma 78

Biopharma Marketing Sales Medicine 78

PM360

FEBRUARY 1, 2024

Embarking on the journey from product development to market success in the biopharma industry is no small feat. According to a McKinsey report , a startling 40% of biopharma products fail to meet their sales forecasts within the initial two years, prompting a critical reassessment of strategies for product launches.

Biopharma 59

Biopharma Competition Prescription Marketing 59

European Pharmaceutical Review

SEPTEMBER 4, 2023

The biopharma company will be required to seek prior approval before acquiring related products. Divest to invest: the new normal in biopharma? The post FTC order could ease biopharma competition appeared first on European Pharmaceutical Review. The FTC has settled on a proposed consent order with Amgen Inc.

Competition 77

Competition Biopharma Pharmaceutical Government 77

Fierce Pharma

OCTOBER 30, 2023

As sales of their GLP-1 diabetes and obesity drugs have surged, Eli Lilly and Novo Nordisk have become the most valuable biopharma companies in the United States and Europe, respectively. That didn | It was no surprise that GLP-1 drugmakers Eli Lilly and Novo Nordisk saw market-cap gains of 16.1% in the third quarter.

Marketing 253

Marketing Biopharma Sales 253

Fierce Pharma

JUNE 6, 2023

Novo Holdings and Gurnet Point have added antibiotics maker Paratek Pharma to their fold in a biopharma M&A deal worth approximately $462 million. Paratek's key selling point is its antibiotic, Nuzyra, which was expected to garner $500 million in peak sales at the time of its 2018 approval.

Biopharma 240

Biopharma Pharma Sales 240

pharmaphorum

DECEMBER 15, 2022

Woxström, a 26-year veteran of AstraZeneca, will lead sales, marketing, and commercial operations for 30 European countries plus Canada. Skin health-focused biopharma Almirall announced a CEO shakeup early in November, with Gianfranco Nazzi stepping down “to pursue new professional opportunities”. Other biopharma hires.

Biopharma 52

Biopharma Pharma Sales Management 52

Zymewire

JANUARY 26, 2023

Review of 2022 Biopharma funding: How should sales teams at service providers adapt for 2023?

Biopharma 52

Biopharma Sales 52

PM360

DECEMBER 16, 2022

Strategic reporting efforts are fundamental to support sales force efficiency and effectiveness. Biopharma companies that do not prioritize reporting strategy find even the strongest sales force will struggle. Reports for sales teams should be concise, with insights that are easy to access and use.

Sales 97

Sales Biopharma Management Patients 97

pharmaphorum

JUNE 27, 2022

per share for Cambridge, Massachusetts-based Epizyme – valuing the US company at around $247 million – and is also promising a further contingent value right (CVR) payment of up to $1 per share if Tazverik (tazemetostat) achieves certain development and sales targets. Ipsen is offering $1.45 Ipsen’s CVR offer includes $0.30

Biopharma 94

Biopharma Sales Prescription FDA 94

European Pharmaceutical Review

DECEMBER 6, 2022

An analysis of GlobalData’s Pharmaceutical Intelligence Center Drugs Database revealed that despite a drop in sales of COVID-19 antibody, REGEN-COV, due to ineffectiveness against Omicron variant, Regeneron experienced record US sales of $1.63 billion in Q3 from its eye disease drug Eylea. percent market capitalisation decline.

Biopharma 71

Biopharma Marketing Food and Drug Administration Sales 71

Zymewire

JANUARY 24, 2024

A must-read for sales professionals navigating the terrain of biotech and pharma funding Unlocking the financial pulse of the biotech and pharma industry.

Biopharma 52

Biopharma Pharma Sales 52

The Marketing Advantage

JUNE 27, 2022

June 27, 2022 The payout curve against which a sales force is compensated has tremendous ability to motivate the sales force to drive sales—so much so that we are dedicating a three-part series to biopharma payout curve design. PAYOUT THRESHOLD Start very early to immediately engage the sales force.

Biopharma 52

Biopharma Sales Competition Marketing 52

The Marketing Advantage

AUGUST 7, 2023

August 7, 2023 Critical to the productivity and efficiency of your sales force is ensuring the optimal targets are being identified and assigned the proper call frequency. Request a free consultation with us today to get started on revitalizing your targeting and call plan strategy to ensure maximum sales force productivity and efficiency.

Biopharma 52

Biopharma Consulting Sales 52

The Marketing Advantage

APRIL 6, 2022

April 6, 2022 One of the most important elements of biopharma sales compensation design is determining the amount of incentive compensation that will be paid out for each level of performance, also referred to as the payout curve. Let's Talk about Payout Curves. What are the Core Payout Curve Shapes?

Biopharma 52

Biopharma Sales Medical Pharmaceutical 52

The Marketing Advantage

DECEMBER 5, 2022

December 5, 2022 Next to a sales compensation plan, no activity motivates a sales force more than a contest. When designed correctly, a contest is a useful and cost-effective way of creating excitement and action around a particular product or activity that a biopharma company would like to emphasize. getting new prescribers).

Biopharma 52

Biopharma Sales Medicine Management 52

pharmaphorum

AUGUST 2, 2022

Traditionally, the foundation of pharmaceutical sales has been in-person visits between sales representatives and healthcare professionals (HCPs), which include events, conferences, dinners, and in-office visits. What does this shift look like for the role of the sales rep moving forward? READ THE FULL ARTICLE HERE.

Sales 52

Sales Biopharma Pharmaceutical Sales Education 52

The Marketing Advantage

OCTOBER 6, 2023

October 6, 2023 One of the most challenging aspects of utilizing a sales compensation plan that does not have a fixed budget is that, too often, the plan ends up paying more or less than expected. In this blog post, we will explore what a budget risk analysis is and what its primary benefits are.

Sales 52

Sales Consulting Biopharma Management 52

pharmaphorum

AUGUST 5, 2022

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. The pace of innovation in biopharma has rocketed over the last two years, with vaccines, new antivirals, and therapies delivered at an unprecedented pace. April 2022. [3] May 2021. [4] March 2022.

Biopharma 52

Biopharma Marketing Pharma Relationship management 52

The Marketing Advantage

APRIL 26, 2022

May 9, 2022 Designing the right payout curve for a biopharma sales force is critical to driving sales force motivation and overall sales. Rank order sales compensation plans are typically never as effective or motivating as goal-based, commission-based or grid-based plans. Let's Talk about Payout Curves.

Biopharma 52

Biopharma Sales 52

Pharmaceutical Technology

SEPTEMBER 20, 2022

Additionally, Versantis is entitled to get one-third of the net proceeds from the sale of the Priority Review Voucher of paediatric application for VS-01 to a third party by Genfit. The post Genfit agrees to acquire biopharma firm Versantis for $109m appeared first on Pharmaceutical Technology.

Biopharma 59

Biopharma Sales Management Pharmaceutical 59

pharmaphorum

DECEMBER 23, 2022

Rarely are organisations able to view HCP relationships holistically – across clinical, medical, and sales – or reap the benefits of creating a unified understanding of the customer. In 2023, omnichannel behaviours will directly influence incentive compensation models by correlating successful engagement data to successful sales outcomes.

Marketing 94

Marketing Sales Medical Patients 94

The Marketing Advantage

OCTOBER 5, 2021

Nevertheless, rank order plans continue to be utilized and, in fact, have increased in use throughout the COVID-19 pandemic due to the ability to control how much will be paid out to the sales force. This blog will explore four limitations of rank order plans that demonstrate how such plans ultimately leave sales on the table.

Sales 52

Sales Biopharma Marketing 52

PharmExec

JUNE 8, 2023

With the sales boom from COVID-19 products now in the rear-view, a resetting is underway for those in Pharm Exec’s listing of the top biopharma producers—shifting attention to new Rx roads ahead and the steady strategies needed to navigate a bumpy business terrain.

Biopharma 98

Biopharma Sales 98

The Marketing Advantage

SEPTEMBER 11, 2023

September 11, 2023 One of the most popular sales compensation design types utilized in the life sciences industry is the commission-based design. Major Commission Frameworks A commission-based sales compensation plan is a plan in which each sales representative earns a certain amount of compensation for each unit (i.e.,

Sales 52

Sales Consulting Biopharma Prescription 52

The Marketing Advantage

NOVEMBER 30, 2021

The severity and impact of the Omicron variant is still being assessed, forcing biopharma companies to grapple with immense uncertainty during one of the most important planning periods of the year, including 2022 sales incentive compensation planning. TERRITORY-LEVEL CONTINGENCY PLAN. 100%/80%) in order to make the territory whole.

Sales 52

Sales Biopharma Competition Medical 52

Pharmaceutical Technology

DECEMBER 20, 2022

Eli Lilly saw strong global drug sales of $187m in Q3 for Mounjaro (tirzepatide), its new type 2 diabetes therapy, which was approved by the FDA in May 2022, according to GlobalData’s Drugs Database Pharma Intelligence Center. and 16.2%, respectively, over Q3 as concerns that sales of their Covid-19 vaccines may start to decline soon.

Biopharma 52

Biopharma Marketing Competition Sales 52

PharmaTech

JANUARY 9, 2024

Bradley Grobler, Vice President of Sales, Pharma & Biopharma Europe, describes how Actylis meets global demands for (bio)pharmaceutical development and manufacturing programs during CPhI 2023.

Manufacturing 52

Manufacturing Biopharma Pharma Sales 52

pharmaphorum

JULY 27, 2022

Demerging Haleon has allowed GSK to focus on higher-margin prescription medicines and vaccines, as well as provide cash for investment in its biopharma pipeline. GSK’s HIV business, run through joint venture company ViiV Healthcare, also had a good quarter with sales up 14% to £1.4 Total revenues came in at £6.9 billion ($8.3

Sales 52

Sales Biopharma Prescription Medicine 52

The Marketing Advantage

JULY 10, 2023

July 10, 2023 One of the functions most critical to maximizing the productivity and efficiency of the sales force’s efforts is call planning —how often a physician target should be seen by a sales representative. Why Don’t Sales Representatives Follow Call Plans? Why Don’t Sales Representatives Follow Call Plans?

Sales 40

Sales Consulting Specialization Prospecting 40

The Marketing Advantage

MAY 8, 2023

Nevertheless, launching a rare disease product continues to be incredibly challenging; in extreme cases, companies have even chosen to cease all commercial sales efforts for their rare disease treatment. However, patients may see several physicians before being diagnosed, meaning a small sales force may need to service many physicians.

Sales 52

Sales Physicians Consulting Education 52

The Marketing Advantage

APRIL 6, 2021

April 6, 2021 The biopharma industry rightfully places a great deal of emphasis on the importance of having a sales compensation plan that pays for performance. Most consider a sales compensation plan to pay for performance if a sales representative who sells more gets paid more. is passable and any rating less than 3.0,

Sales 52

Sales Biopharma Marketing Specialization 52

The Marketing Advantage

OCTOBER 3, 2022

October 3, 2022 With 2023 sales compensation planning underway, many biopharma companies are considering whether or not they should change their sales compensation plan and, if so, how much. In this blog post, we will explore four such indicators that it is time to change your sales compensation plan. <10%. .

Sales 52

Sales Biopharma Leads Marketing 52

The Marketing Advantage

SEPTEMBER 2, 2022

September 2, 2022 One of the biggest challenges biopharma companies face around designing a sales compensation plan for a multi-product bag is ensuring that all products in the bag get sufficient attention without taking focus away from the product(s) deemed most important. Depending on the design of the sales compensation plan (i.e.,

Sales 40

Sales Biopharma 40

PharmExec

JUNE 13, 2022

Kraus brings more than 25 years of experience leading life sciences companies, including global responsibility for customer strategy, sales, operations, and various support functions.

Biopharma 52

Biopharma Sales Leads 52

The Marketing Advantage

SEPTEMBER 7, 2021

In parallel with this growing industry-wide complexity has been the call to further simplify sales compensation plans. Bridging this increasingly growing divide is not easy and raises the question of what truly makes a sales compensation plan simple. ATTRIBUTE 2 Simple to administer. Simple to understand. Simple to administer.

Sales 52

Sales Biopharma Marketing Management 52

The Marketing Advantage

JANUARY 30, 2023

January 30, 2023 Although the limitations of forced rank sales compensation plans make them ineffective for any stage of the product life cycle, the stage in which they tend to be most popular—the launch stage —is also the stage in which they do the most harm. top 10%, then next 10%, etc.). Let’s explore why.

Sales 40

Sales Consulting Biopharma Leads 40

PharmaTech

MAY 26, 2023

Myrna Wilson, director, Global Marketing, Strategic Growth and Technical Sales, Pharmaceutical Ingredients, Univar Solutions, discusses the state of the biopharma supply chain, movements in the patent industry, and more.

Pharmaceutical 52

Pharmaceutical Biopharma Sales Marketing 52